Lindus Therapeutics

Lindus Therapeutics is a next-generation drug development company focused on building a portfolio of in-licensed clinical-stage therapeutic assets. Originally founded in 2021 as Lindus Health, a technology-first clinical research organization (CRO), the company transitioned to internal asset development as Lindus Therapeutics in 2026 after selling its CRO assets to Curavit Clinical Research. The company leverages its proprietary AI systems and integrated clinical trial execution platform, Citrus, to advance its portfolio more efficiently than traditional biopharma models. Lindus Therapeutics targets non-ultrarare chronic diseases across core therapeutic areas such as cardiometabolic, respiratory, psychiatry, dermatology, and women's health. Backed by prominent investors like Peter Thiel and Balderton Capital, the company aims to launch its first clinical trials in early 2027.